Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Internal and Emergency Medicine
Published in: Internal and Emergency Medicine 2/2008

01-06-2008 | CE - Letter to the Editor

Plasma derived protein C in severe sepsis: report of two cases

Authors: A. Tuttolomondo, A. Pinto, D. Di Raimondo, P. Fernandez, G. Licata

Published in: Internal and Emergency Medicine | Issue 2/2008

Login to get access

Excerpt

Severe sepsis is defined as sepsis-associated organ dysfunction, (arterial hypoxemia, acute oliguria, coagulation abnormalities, thrombocytopenia, hyperbilirubinemia), hypoperfusion (hyperlactatemia) and arterial hypotension (mean arterial pressure <70 mmHg, or a systolic blood pressure decrease >40 mmHg) [3, 4]. Septic shock [3, 4] is defined as acute circulatory failure induced by sepsis with hypotension despite adequate fluid resuscitation. …
Literature
1.
Abraham E, Laterre PF, Garg R et al (2005) Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl JMed 353:1332–1341CrossRef
2.
Bernard GR, Vincent JL, Laterre PF et al (2001) Recombinant human protein C worldwide evaluation in severe sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699–709PubMedCrossRef
3.
Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJl (1992) Definitions of sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. Chest 101:1644–1655PubMedCrossRef
4.
Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM (2004) Surviving sepsis campaign guidelines for the management of severe sepsis and septic shock. Crit Care Med 32:858–873PubMedCrossRef
5.
Deventer SJ, ten Cate JW (1995) Coagulation activation and tissue necrosis in meningococcal septic shock: severely reduced protein C levels predict a high mortality. Thromb Haemost 73:15–20PubMed
6.
Ettinghausen CE, Veldmann A, Beeg T, Schneider W, Jager G, Kreuz W (1999) Replacement therapy with protein C concentrate in infants and adolescents with meningococcal sepsis and purpura fulminans. Semin Thromb Hemost 25:537–541CrossRef
7.
Esmon CT (2001) Role of coagulation inhibitors in inflammation. Thromb Haemost 86:51–56PubMed
8.
Fijnvandraat K, Derkx B, Peters M, Bijlmer R, Sturk A, Prins MH, van Deventer SJ, ten Cate JW (1995) Coagulation activation and tissue necrosis in meningococcal septic shock: severely reduced protein C levels predict a high mortality. Thromb Haemost 73:15–20PubMed
9.
Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, Marey A, Lestavel P (1992) Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 101:816–823PubMedCrossRef
10.
Fourrier F, Leclerc F, Aidan K et al (2003) Combined antithrombin and PC supplementation in meningococcal purpura fulminans: a pharmacokinetic study. Intensive Care Med 29:1081–1087PubMedCrossRef
11.
Green C, Dinnes J, Takeda AL, Cuthbertson BH (2006) Evaluation of the cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom. Int J Technol Assess Health Care 22:90–100PubMedCrossRef
12.
Levi M, ten Cate H, van der Poll T, van Deventer SJ (1993) Pathogenesis of dissemnated intravascular coagulation in sepsis. JAMA 270:975–979PubMedCrossRef
13.
Levi M, van der Poll T, ten Cate H, van Deventer SJ (1997) The cytokine mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia. Eur J Clin Invest 27:3–9PubMedCrossRef
14.
Lorente JA, Garcia-Frade LJ, Landin L, de Pablo R, Torrado C, Renes E, Garcia-Avello A (1993) Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest 103:1536–1542PubMedCrossRef
15.
Macias WL, Nelson DR (2004) Severe protein C deficiency predicts early death in severe sepsis. Crit Care Med 32(5 Suppl):S223–S228PubMedCrossRef
16.
Rintala E, Kauppila M, Seppala OP et al (2000) Protein C substitution in sepsis-associated purpura fulminans. Crit Care Med 28:2373–2378PubMedCrossRef
17.
Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M (2001) Early goal-directed therapy collaborative group early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345:1368–1377PubMedCrossRef
18.
Vincent JL, Angus DC, Artigas A et al (2003) Effects of drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 31:834–840PubMedCrossRef
19.
Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R (2001) Intensive insulin therapy in the critically ill patients. N Engl J Med 345:1359–1367PubMedCrossRef
20.
21.
White B, Livingstone W, Murphy C, Hodgson A, Rafferty M, Smith OP (2000) An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans–associated meningococcemia. Blood 96:3719–3724PubMed
Metadata
Title
Plasma derived protein C in severe sepsis: report of two cases
Authors
A. Tuttolomondo
A. Pinto
D. Di Raimondo
P. Fernandez
G. Licata
Publication date
01-06-2008
Publisher
Springer Milan
Published in
Internal and Emergency Medicine / Issue 2/2008
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-008-0107-5

Other articles of this Issue 2/2008

Internal and Emergency Medicine 2/2008 Go to the issue

CE - Letter to the Editor

Idiopathic retroperitoneal fibrosis: a rare disease to be treated by an internist

CE - Letter to the Editor

Controversies in the “pill in the pocket” approach to atrial fibrillation

IM - Review

Optimizing management of metabolic syndrome to reduce risk: focus on life-style

IM - Commentary

Should cancer patients receive thromboprophylaxis to prevent catheter-related upper limb deep vein thrombosis?

CE - Letter to the Editor

Microscopic polyangiitis with sexual and reproductive system involvement: first description of a case

EM - Airway Forum

Acute shortness of breath 10 years post laryngectomy
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits